An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
收藏DataCite Commons2026-01-21 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012679/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
提供机构：
Vivli
创建时间：
2026-01-21
